STAT1mon
Pharmalittle: We’re reading about Congress reining in PBMs, Sanofi suing HHS, and more
Sanofi has filed a lawsuit accusing the Biden ... it proceeded with plans to issue credits to hospitals covered by the 340B Drug Discount Program for medicines ordered at full price from a wholesaler.
STAT1mon
Pharmalittle: We’re reading about Novo Holdings proceeding with Catalent deal, Sanofi threatened with sanctions, and more
In a Dec. 13 letter, the Health Resources & Services Administration said that if Sanofi proceeds with its plan, the company could be terminated from the 340B Drug Discount Program. The agency also ...
Sanofi's Blood Cancer Drug's New Subcutaneous Formulation Hits Primary Goal In Late-Stage In Multiple Myeloma
Sanofi's phase 3 study shows Sarclisa SC matches IV formulation in efficacy for relapsed myeloma. Regulatory submissions are planned for 2025.
The Pharma Letter12h
Novartis sues US health agency over drug rebate model
Novartis sues HHS over rejection of a proposed 340B rebate model, arguing it enhances transparency and compliance while ...
pharmaphorum1d
BMS files legal challenge to HHS' 340B rebate decision
The 340B requirement has long been a bone of contention ... Last year, for example, a federal appeals court sided with Sanofi, AstraZeneca, and Novo Nordisk in a dispute claiming that recipients ...
Benzinga.com1mon
STAT+: Feds threaten Sanofi with sanctions over plan to change payment terms for a federal drug discount program
In a Dec. 13 letter, the Health Resources & Services Administration said that if Sanofi proceeds with its plan, the company could be terminated from the 340B Drug Discount Program. The agency also ...